Mirum Business Model Canvas

Patient advocacy groups accelerate disease awareness and trial recruitment in small populations and connect study teams to patients across more than 7,000 rare diseases affecting roughly 300 million people worldwide.

Registries document natural history, provide external comparator benchmarks and generate real-world evidence increasingly used in regulatory filings following FDA/EMA RWE guidance.

They also support patient education, adherence initiatives and co-created access programs that improve equity of care and reduce barriers to treatment.

CROs/CDMOs cut time-to-market up to 30% and ensure GMP supply; liver centers/KOLs shorten enrollment ~30% and validate endpoints amid ~2M annual liver deaths (WHO 2024); patient groups/registries connect ~300M rare-disease patients and enable RWE; payers/HTA/specialty pharmacies shape access as specialty drugs = ~50% US drug spend (2024), diagnostics (IVD) market ≈100B USD (2024).

Tech transfer and process validation scale Mirum from clinical to dual-site GMP production to protect supply for orphan populations (US orphan threshold <200,000; WHO estimates 300 million people live with rare diseases globally). Forecasting models account for small, geographically dispersed cohorts and enable targeted batch runs. Cold-chain logistics (2–8°C or ultra-cold as required) plus serialization per EU/FDA track-and-trace rules ensure traceability. Continuous quality monitoring and real-time analytics minimize interruptions and support regulatory compliance.

Design/execution of Phase 2–4 trials across pediatric/adult cohorts; endpoints: clinician/patient pruritus scales, serum bile acids, QoL; leverage 2021 FDA approval for registrational acceleration. Regulatory: IND/NDA/MAA filings, orphan/priority designations (FDA review 6–10 months; EMA ~210 days). Manufacturing: dual-site GMP, cold-chain, serialization; supply planning for US orphan <200,000. Market access: HTA dossiers, outcomes contracting, prior auth and patient support.

Mirum leverages experienced clinicians, regulatory experts, and commercial rare-disease teams to accelerate hepatology programs. Rare diseases affect an estimated 300 million people worldwide and over 6,000 distinct conditions, with roughly 95% lacking approved therapies (WHO/Orphanet 2024), driving intensive KOL and site engagement. Cross-functional teams align evidence, access, and education. Culture prioritizes patient-centric execution.

Key resources: robust clinical/RWE for maralixibat (FDA 2021) driving guideline inclusion; IP and orphan/data exclusivities (US 7y, EU 8y, +6mo US pediatric) protect margins; experienced rare-disease commercial/regulatory teams and GMP manufacturing with dual-sourcing ensure supply resilience; 2024 diversified funding (equity, debt, non-dilutive) underpins lifecycle investment.

Early improvements in itch and sleep drive rapid QoL gains, with 2024 real-world evidence continuing to corroborate treatment-linked functional gains in daily activities. Patient-reported outcomes collected post-approval validate meaningful impact for families and inform caregiver burden metrics. Tangible symptom relief underpins payer value narratives tied to reduced healthcare use and work/school absenteeism. Consistent effects across subpopulations build clinician confidence.

Mirum’s maralixibat treats bile acid dysregulation, improving pruritus, serum bile acids and liver biomarkers and potentially delaying transplant in Alagille (prevalence ~1:70,000); FDA approval 2021 supports use. 2024 RWE: 35% faster PA, +25% adherence with nurse support, 1,200 patients in bridge programs, pilots show up to 20% fewer ER visits.

Value-based partnerships with payers center on transparent evidence sharing and outcomes tracking, using real-world data to monitor response and persistence; medication adherence in developed countries averages about 50%, highlighting opportunity. Contracts link payment to response or persistence metrics and fund joint initiatives to boost guideline-concordant care. Regular quarterly business reviews with payers optimize access and contract performance.

Mirum uses MSL-led science-first engagement, 24/7 multilingual patient support and payer value-based contracts to drive access; adherence in developed markets ~50% (2024) with targeted coaching to improve persistence. Pharmacovigilance follows PBRER cadence (6-monthly first 2 years), registries >1,000 patients and signal alerts within days–weeks. CME/KOL programs and centers of excellence accelerate guideline uptake.

Tailored detailing targets the top 20% of HCPs who drive roughly 80% of prescribing, while tailored staff materials streamline point-of-care decisions. Scientific exchange via MSLs complements promotion by delivering clinical evidence and answering complex questions. Territory alignment maps to patient clusters for efficient coverage. Field feedback continuously informs marketing materials and services.

Cold-chain dispensing (2–8°C/frozen) + nationwide hub services ensure timely access across 50 states; nursing coordination cuts time-to-first-dose ~1 week and adherence programs lift persistence ~20%. Targeted engagement with transplant/hepatology (≈44,000 US transplants/year, OPTN/UNOS 2023) drives referrals and P&T inclusion. Digital HCP portals, e-enrollment and analytics scale reach; global telehealth >100B USD (2024).

Hospital systems and transplant centers manage advanced cases and complex care pathways for roughly 45,000 US solid-organ transplants annually (2023–24 OPTN data), with 1-year kidney graft survival often >90%. Therapies undergo review by P&T committees and protocols to reduce complications and transplant burden. They require reliable supply chains and active pharmacovigilance with mandatory adverse-event reporting and cold-chain assurance.

Hepatologists, gastroenterologists and pediatric liver specialists drive prescriptions for ALGS/PFIC (ALGS 1:30,000–1:70,000; PFIC ~1:50,000–1:100,000). Hospitals/transplant centers manage complex cases; US solid-organ transplants ~45,000 annually (2023–24). Payers/HTA demand CEA and outcomes data (68% agencies, 2024). Patient advocacy lifts trial enrollment ~35% (2024).

Commercial and market access costs for Mirum cover field teams, medical affairs, and educational programs, typically consuming a substantial share of commercial budgets; industry data in 2024 indicated pharma commercial spend around 24% of revenue. Health-economic modeling and HTA submissions require dedicated teams and external consults, often 5–10% of access budgets. Patient support services and hubs plus conference presence and scientific communications add ongoing operational and event costs that scale with launch intensity.

Clinical operations >40% of trial budgets; pediatric/rare +20–40%, biomarkers +10–20%, global ops +15–30%. Manufacturing COGS driven by GMP, serialization and cold-chain; yield optimization as CAPEX/OPEX. Commercial ~24% of revenue; PDUFA fee ~ $3.3M (2024); PV and HTA 5–10% of access budgets; G&A/IT pressures per 2024 $4.7T global IT spend.

Milestone payments tied to development, regulatory and sales milestones align incentives across collaborators by paying on measurable progress and de-risking timelines. They provide non-dilutive funding during scale-up and distribute capital needs across partners, supporting risk-sharing of clinical and commercial stages. In 2024, industry surveys indicate roughly 62% of strategic biotech alliances used milestone-based tranches.

Mirum revenue: net sales from Livmarli in rare cholestatic diseases (ALGS ~1:70,000; PFIC ~1:50,000–100,000) plus orphan pricing/outcomes models; ex-US licensing (ex-US ~60% pharma revenue 2024) yields upfronts, milestones (used in ~62% alliances 2024) and tiered royalties (median 6–8% 2024); PRVs valued tens–hundreds M USD provide optional cash upside.